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ABSTRACT
Introduction Lateral compression type 1 (LC1) pelvic 
fractures are the most common type of pelvic fracture. The 
majority of LC1 fractures are considered stable. Fractures 
where a complete sacral fracture is present increases 
the degree of potential instability and have the potential 
to displace over time. Non- operative management of 
these unstable fractures may involve restricted weight 
bearing and significant rehabilitation. Frequent monitoring 
with X- rays is also necessary for displacement of the 
fracture. Operative stabilisation of these fractures may be 
appropriate to prevent displacement of the fracture. This 
may allow patients to mobilise pain- free, quicker.
Methods and analysis The study is a feasibility study to 
inform the design of a full definitive randomised controlled 
trial to guide the most appropriate management of these 
injuries. Participants will be recruited from major trauma 
centres and randomly allocated to either operative or 
non- operative management of their injuries. A variety of 
outcome instruments, measuring health- related quality 
of life, functional outcome and pain, will be completed at 
several time points up to 12 months post injury. Qualitative 
interviews will be undertaken with participants to explore 
their views of the treatments under investigation and trial 
processes.
Eligibility and recruitment to the study will be analysed to 
inform the feasibility of a definitive trial. Completion rates 
of the measurement instruments will be assessed, as well 
as their sensitivity to change and the presence of floor or 
ceiling effects in this population, to inform the choice of 
the primary outcome for a definitive trial.
Ethics and dissemination Ethical approval for the 
study was given by the South West—Central Bristol 
NHS Research Ethics Committee on 2nd July 2018 (Ref; 
18/SW/0135). The study will be reported in relevant 
specialist journals and through presentation at specialist 
conferences.
Trial registration number ISRCTN10649958
InTRoduCTIon
Background
The Trauma Audit and Research Network 
(TARN) database indicate increasing 
numbers of pelvic ring fractures. In the finan-
cial year 2015/16, TARN recorded 6407 pelvic 
ring fractures in England and Wales of which 
half were associated with high- energy trauma. 
Fractures associated with a side or lateral 
compression force are the most common; a 
subgroup of these are called lateral compres-
sion type 1 (LC1). LC1 fractures make up 
approximately 60% of pelvic ring fractures,1 2 
which equates to approximately 3800 patients 
a year within England and Wales. A propor-
tion of pelvic fractures are sustained as a result 
of simple trips or falls and these are gener-
ally in the older person where bone quality is 
frequently poor. Stabilisation of fractures in 
elderly patients presents technical problems 
due to the difficulty in achieving adequate 
fixation in osteoporotic bone. The mortality 
Strengths and limitations of this study
 ► This is the first randomised multicentre study to in-
vestigate the treatment of high- energy unstable LC1 
fractures.
 ► We are collecting a range of outcome measures at 
several time points to identify the most appropriate 
primary outcome for a definitive study.
 ► Qualitative interviews will provide valuable insights 
to identify challenges with recruitment and follow- 
up and inform the future definitive study design.
 ► Results of the TULIP feasibility will inform the design 
and conduct of a future multicentre Randomised 
Controlled Trial.
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Box 1 detailed study objectives
1. To produce a Consolidated Standards of Reporting Trials diagram, 
reporting screening, recruitment, randomisation compliance and 
include allocation proportions by centre.
2. To confirm the recruitment rates and percentage of eligible patients 
who agree to take part.
3. To collect outcome data at fixed time points post injury to collate 
the completeness and spread of the data at different time points 
post injury.
4. To identify the outcome measure to be used as the primary outcome 
on the basis of completeness of data, sensitivity to change over time, 
the presence of floor or ceiling effects and patient acceptability.
5. To develop and refine methods for the collection of resource use 
data relating to both management pathways.
6. To explore patient and staff views of randomisation, treatment and 
trial processes using qualitative interviews.
during index hospital admission associated with LC1 frac-
tures ranges from 5.1% to 8.6%.1 2
LC1 fracture patterns are a heterogeneous group of 
injuries, divided into those involving a complete or an 
incomplete fracture of the sacrum with or without an 
injury to the anterior pelvic ring.
The majority of LC1 fractures are considered stable 
enough to allow rehabilitation without later displace-
ment. Numerous studies have shown complete sacral 
fractures to be present in 32%–50% of LC1 fractures.3–5 
The combination of a complete sacral fracture and either 
unilateral or bilateral pubic rami fractures increases the 
degree of potential instability. Unstable LC1 fractures 
of the pelvis have a tendency to displace significantly 
over time.6 Bruce et al5 reported 32% of patients with a 
complete sacral fracture and unilateral pubic rami frac-
tures, and 68% of patients with a complete sacral fracture 
and bilateral rami fractures, went on to have significant 
displacement.
This, potentially unstable, subgroup of LC1 fractures 
may still be managed non- operatively. Patients would 
usually be allowed to mobilise as able although they may be 
advised to restrict the amount of weight they put through 
the injured side and will require walking aids provided 
by a physiotherapist. They also require frequent X- rays 
to monitor for any progression in fracture displacement. 
Patients with LC1 fractures are reported to spend up to 
16 days in hospital following their injury7 and require 
significant rehabilitation following their discharge from 
acute care.8 These injuries can have significant implica-
tions for patients. Hoffmann et al9 showed that even at 
24 months postinjury, patients had not returned to their 
preinjury functional abilities. Aprato et al8 found that 
60% of the costs following pelvic injury were attributed to 
health- related work absence.
It may therefore be appropriate to surgically stabilise 
this subgroup of more severe, potentially unstable, LC1 
fractures. This involves the insertion of metalwork to 
prevent displacement of the fractures. While patients will 
still require walking aids, their ability to mobilise may be 
improved. Tosounidis et al7 carried out a non- randomised 
study comparing surgical versus non- surgical manage-
ment of LC1 fractures. They found that patients had 
significantly decreased pain at 72 hours and were able 
to mobilise, pain- free, quicker following surgery. They 
also demonstrated a shorter length of stay in patients 
undergoing surgical fixation. However, Hagen et al10 in 
a retrospective study looking at patients’ pain, narcotic 
use and mobility following surgical stabilisation of lateral 
compression fractures found no significant difference in 
these parameters between surgically and non- surgically 
treated groups.
Other advantages of treating these fractures surgically 
include a lower risk of fracture displacement and avoiding 
the risks associated with immobility, including chest or 
urinary tract infection, thrombosis and pressure sores. 
The disadvantages of treating LC1 fractures surgically are 
the risk of general anaesthesia, the physiological impact 
of surgery, the small risk of surgical site infection and of 
damage to the nerves that supply the bladder, bowel or 
leg muscles. As well as improving patients’ pain levels and 
functional abilities, surgery has been shown to provide 
economic benefits by reducing length of hospital stay and 
input required from healthcare professionals, which may 
outweigh the additional costs of surgery.
Rationale
A survey on the management of LC1 fractures,11 although 
not specific to unstable LC1 fractures, indicated signifi-
cant variation of practice in managing these fractures and 
agreement between surgeons was only achieved for one 
third of case studies.
Both Hagen et al10 and Tosounidis et al7 concluded that 
a randomised controlled trial of surgical versus nonsur-
gical management of LC1 fractures was needed. Currently 
there is no level 1 evidence available to guide clinicians as 
to the optimum management of these patients.
Aim and objectives
The overarching aim is to perform a definitive trial to 
establish whether surgical or non- surgical management 
of unstable LC1 fractures is most appropriate. The aim of 
this feasibility study is to allow us to plan a full definitive 
trial by measuring recruitment, retention and follow- up 
rates and explore participant and staff views of the trial 
processes. Study objectives are shown in box 1.
METhodS And AnAlySIS
Trial setting
This multicentre trial will take place in 9 NHS Major 
Trauma Centres (MTC) which specialise in the treatment 
of pelvic injuries over 33 months. There are 22 MTCs 
across the UK currently where all patients with unstable 
pelvic injuries will be referred and assessed.
Eligibility
All patients over 16 years of age presenting with an LC1 
fracture including a complete sacral fracture will be 
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Figure 1 Study flow diagram.
assessed for inclusion in the study. A log of all patients 
meeting these criteria will be maintained. Patients will be 
excluded if they meet one of the following criteria:
 ► Unable to be randomised within 72 hours of having 
capacity to comprehend the study information 
following arrival at the major trauma centre.
 ► Fragility fractures resulting from low- energy trauma 
(fall from less than standing height).
 ► Presenting medical condition which precludes 
surgical intervention.
 ► Unable to provide informed consent.
Recruitment
Patients eligible for inclusion in the study will be iden-
tified by their surgeon who will make the patient aware 
of the study and seek their agreement to consider partic-
ipating. The study will then be fully discussed with the 
patient by a member of the research team at each site. 
Patients will be provided with a written information sheet 
explaining the purpose of the study and the treatments 
under investigation. They will be allowed sufficient time 
to consider the information provided and patients who 
agree to participate in the study will be asked to provide 
written consent. Patients who decline to participate in the 
study will be recorded on the screening log together with 
reasons for declining where provided.
To understand patient perceptions of the recruitment 
process, all patients that are approached regarding 
their potential participation in the study will be asked 
to complete a short questionnaire regardless of whether 
they consent to participate in the feasibility study. Patients 
will be asked to complete these questionnaires immedi-
ately following confirmation of their decision on partic-
ipating in the study. Where this is not possible a copy 
of the questionnaire will be sent in the post by the local 
research team. Responses to these questionnaires will 
be confidential and patients will be identified only by 
their screening ID. The results of this questionnaire will 
be analysed as an ongoing process to help inform and 
develop the approach of further patients.
Figure 1 shows the flow of participants through the trial.
Allocation and blinding
Patients will be randomly allocated to the treatments on 
a 1:1 basis using a web- based randomisation procedure 
hosted by Bristol Randomised Trials Collaboration (a 
registered Clinical Trials Unit) with concealment prior 
to consent, but no blinding of participants or clinical 
staff to the allocation of treatment pathway. The trial 
statistician is responsible for producing the allocation 
sequence, stratified by recruiting centre and minimised 
on Injury Severity Score as an indicator of multiple inju-
ries (<16 or>=16).
Interventions
Surgical management
Surgical management will involve fixation of the pelvic 
fracture by a specialist pelvic surgeon at the earliest 
opportunity. As surgical fixation of these fractures is 
performed regularly in all participating centres the 
method of fixation and choice of implant will be left to 
the operating surgeon. Postoperative management and 
rehabilitation will be left to the discretion of the treating 
surgeon. Details on the surgery and subsequent rehabili-
tation will be collected as part of the study.
Non-surgical management
Non- surgical management will be left to the discretion of 
the treating surgeon. Any decision on restricted weight- 
bearing will be left to the treating surgeon. Rehabilitation 
including Physiotherapy and Occupational Therapy will 
follow usual practices. Details on the rehabilitation will be 
collected as part of the study.
outcomes
To assess the feasibility of the study design we will assess 
participant numbers such as recruitment rate, including 
numbers of patients meeting inclusion criteria and 
reasons for exclusion or declining where appropriate 
Compliance rates with allocated treatment and any 
reasons for not being able to comply. We will also look at 
follow- up rates, withdrawals, including reasons for with-
drawal where appropriate in accordance with the Consoli-
dated Standards of Reporting Trials diagram. We will look 
at the outcomes measures that are expected to be used 
in the full trial with particular interest in data comple-
tion rates, evidence of sensitivity to change (whether the 
score change over time) and whether the outcomes have 
ceiling or floor effects.
The following patient reported outcomes will be tested 
for use in a definitive study:
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Table 1 Visit schedule
Baseline
2 weeks*
(+1 week)
6 weeks*
(±1 week)
3 months*
(±2 weeks)
6 months*
(±3 weeks)
9 months*
(±3 weeks)
12 months*
(±4 weeks)
Inpatient Phone/online Clinic Clinic Post/online Post/online Clinic
Demographics ✓
Injury characteristics ✓
Clinical review ✓ ✓† ✓ ✓ ✓
Surgical details   ✓‡
Rehabilitation   ✓ ✓ ✓ ✓ ✓ ✓
Adverse events ✓ ✓ ✓ ✓ ✓ ✓ ✓
Iowa Pelvic Score ✓§ ✓ ✓ ✓ ✓ ✓ ✓
OHS ✓§ ✓ ✓ ✓ ✓ ✓ ✓
EQ- 5D- 5L ✓§ ✓ ✓ ✓ ✓ ✓ ✓
ICECAP- A ✓ ✓ ✓ ✓ ✓ ✓ ✓
BPI ✓§ ✓ ✓ ✓ ✓ ✓ ✓
TUAG   ✓ ✓ ✓
Resource use   ✓ ✓ ✓ ✓ ✓
*From date of randomisation.
†Non- operative group only.
‡Surgical group only.
§Preinjury and postinjury.
BPI, Brief Pain Inventory; EQ- 5D- 5L, Euroquol - 5 Dimension - 5 level; ICECAP- A, ICEpop Capability measure for Adults; OHS, Oxford Hip 
Score; TUAG, Timed Up and Go.
Measures at baseline and follow-up
Iowa Pelvic Score: A measure specific to outcomes following 
pelvic injury.12 Shows good construct validity when 
compared with the physical component of the SF-36. This 
is also the preferred pelvic specific outcome measure by 
patients13 and the study patient advisory group.
Oxford Hip Score14: A functional score for patients 
following hip injury and/or surgery. While not pelvic 
specific, the activities and symptoms included were felt to 
be relevant by our patient group.
EQ- 5D- 5L15: A standardised instrument of health status.
ICECAP- A16: A measure of capability for the general 
adult population for use in economic evaluation. It 
focuses on well- being in the broader sense, not just health 
status.
Brief Pain Inventory17: Originally developed to measure 
pain in patients suffering from cancer. It has since been 
used in a variety of conditions. It allows patients to rate 
the severity of their pain as well as its influence on their 
psychological health and activity
All participants will complete these questionnaires at 
baseline, 2 and 6 weeks, 3 and 6 months following rando-
misation. Participants recruited in the first 12 months 
of the study will also complete questionnaires at 9 and 
12 months following randomisation. Baseline data will 
be collected at recruitment. Participants will be able to 
complete their follow- up questionnaires in person, when 
attending an outpatient appointment, online or by post. 
Standard care for participants with these injuries would 
be for clinical review in an outpatient clinic at 6 weeks, 
3 months and 12 months (see table 1).
At these time points, in addition to the questionnaires, 
participants will complete a Timed Up and Go assess-
ment.18 This is an assessment of a participant’s phys-
ical walking ability and involves being timed to stand 
from a chair, walk a distance of 3 m and return to sit 
in the chair. Where possible this will be completed by 
an assessor blinded to the participant’s treatment alloca-
tion. Completeness of this assessment will be recorded 
to inform the appropriateness of its use in a definitive 
trial.
Data obtained as part of the study will be entered on 
to a secure password protected online REDCap database.
Study duration
Recruitment will continue for 18 months. Follow- up for 
6 months with 6 months for analysis.
Economic evaluation
The economic feasibility will focus on data collection to 
inform the economic evaluation to be done alongside the 
definitive trial. As well as the EQ- 5D- 5L and ICECAP- A we 
will record length of stay in both study arms, along with 
time spent in theatre and implants used (surgical arm 
only). Use of specific primary, community and social care 
services will be assessed by patient reported resource use 
questionnaires at 6 weeks, 3, 6, 9 and 12 months.
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Qualitative study
To inform the conduct of the definitive trial, we will invite 
up to 20 consented participants (10 from each treatment 
arm and across all sites) to take part in a semi- structured 
telephone interview by the qualitative researcher after 
they have completed the 6- month follow- up question-
naire. The interviews will explore their experience of the 
trial, their treatment and recovery, and acceptability of the 
outcome measures. A purposive sample will be selected 
to reflect maximum variation in socio- demographics, 
age and ethnicity. Topic guides for the interviews will be 
developed from the literature, team discussions and input 
from the PAG. Ten participating healthcare professionals 
(surgeons, research nurses and clinical nurse specialists) 
will be invited to take part in a telephone interview eval-
uating their experiences of treatment and views of trial 
processes.
Safety reporting
Only serious adverse events will be reported for this study 
comparing two treatments in common clinical practice. A 
serious adverse event is any untoward medical occurrence 
that:
 ► Results in death.
 ► Is life- threatening.
 ► Requires inpatient hospitalisation or prolongation of 
existing hospitalisation.
 ► Results in persistent or significant disability/
incapacity.
 ► Consists of a congenital anomaly or birth defect.
Serious adverse events which are expected with these 
injuries are:
 ► Wound complications/infections.
 ► Neurovascular injury.
 ► Thromboembolic events.
 ► Chest infection.
 ► Metal work/implant failure/loosening and non/
mal- union.
Secondary operations to prevent infection, mal- union, 
non- union or for symptoms related to the metalwork may 
also be expected.
Any unexpected serious adverse events will be recorded 
and reported to the Sponsor and Ethics Committee.
Sample size
This feasibility study is designed to produce estimates of the 
parameters required to plan a definitive trial, together with 
enough data on outcome measures to show whether or not 
the ceiling effect on the Iowa instrument is likely to be a 
problem in the definitive trial. If 120 patients are screened 
as eligible and 40% agree to take part, then this will allow 
us to estimate the recruitment rate of 40% with a 95% CI 
of 31%–49% which is within 10% in either direction. Forty 
complete sets of data should be enough to show when a 
ceiling effect starts to occur although this will rely on a 
visual inspection of the data at each time point. If 60 sets of 
data are collected this will allow greater precision.
data analyses
Quantitative data analysis
As this is a feasibility trial no formal statistical testing will 
be carried out. Instead the analysis will focus on reporting 
data that will be used for planning and for assessing the 
feasibility of the definitive trial.
Feasibility parameters with 95% CIs will be provided 
using the exact binomial method. The spread of the data 
and ceiling effects will be documented for all outcome 
variables using histograms for single time points and 
box plots to compare over time. Calculation of the area 
under the curve over time is the likely primary method of 
analysis for the definitive trial, and the feasibility analysis 
will investigate whether this would produce a sufficiently 
complete data set or whether it would be better to focus 
on a particular time point. The 95% CI for the effect sizes 
for all potential outcome measures will be calculated to 
ensure that a future trial can be planned appropriately.
The future economic evaluation is likely to present 
results in cost/Quality Adjusted Life Year (QALY) 
terms reporting within trial and lifetime horizons. The 
economic feasibility work will focus on establishing the 
appropriate methods for collecting the outcomes, both 
costs and utilities, which will be of interest in the future 
economic evaluation, with analysis therefore limited to 
assessment of completeness and descriptive statistics.
Qualitative data analysis
With informed consent, all interviews will be digitally 
recorded, transcribed, anonymised and analysed using 
thematic methods of building codes into themes and 
sub- themes using the process of constant comparison 
(facilitated by NVIVO software: QSR International). This 
aspect is important to understand the acceptability of trial 
processes, including randomisation, treatment pathways 
and other outcome questionnaires for the definitive trial.
Patient and public involvement/patient advisory group
A patient advisory group (PAG) has been involved in the 
development of the study and advising on study design. 
The PAG have been particularly involved in the selec-
tion of appropriate outcome measures and reviewing 
patient facing materials including the information sheets. 
The group will continue to provide advice throughout 
the study and their advice on any changes which may 
improve recruitment and the study will be actively sought. 
A representative of the group will sit on the Trial Steering 
Committee (TSC) to feedback the advice of the group to 
the committee. The PAG will also be actively involved in 
any publication and dissemination of results at the end of 
the study.
dissemination
The findings of the study will be presented locally at each 
participating site and to the general orthopaedic commu-
nity at national orthopaedic conferences. The findings 
will also be submitted for publication in an open access 
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peer- reviewed journal and presented at relevant confer-
ences and research meetings.
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